Alps Advisors Inc. boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 9.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 41,814 shares of the biopharmaceutical company’s stock after buying an additional 3,649 shares during the period. Alps Advisors Inc. owned approximately 0.10% of Ultragenyx Pharmaceutical worth $2,227,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Swiss National Bank raised its holdings in Ultragenyx Pharmaceutical by 1.8% during the 3rd quarter. Swiss National Bank now owns 67,252 shares of the biopharmaceutical company’s stock worth $3,582,000 after buying an additional 1,200 shares during the period. Prudential Financial Inc. raised its holdings in Ultragenyx Pharmaceutical by 162.0% during the 3rd quarter. Prudential Financial Inc. now owns 17,740 shares of the biopharmaceutical company’s stock worth $945,000 after buying an additional 10,970 shares during the period. State of Wisconsin Investment Board raised its holdings in Ultragenyx Pharmaceutical by 44.4% during the 3rd quarter. State of Wisconsin Investment Board now owns 40,445 shares of the biopharmaceutical company’s stock worth $2,154,000 after buying an additional 12,445 shares during the period. Canada Pension Plan Investment Board acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $330,000. Finally, Pictet Asset Management Ltd. raised its holdings in Ultragenyx Pharmaceutical by 27.4% during the 3rd quarter. Pictet Asset Management Ltd. now owns 750,407 shares of the biopharmaceutical company’s stock worth $39,967,000 after buying an additional 161,196 shares during the period. Hedge funds and other institutional investors own 95.97% of the company’s stock.

In related news, CEO Emil D. Kakkis acquired 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, August 28th. The stock was purchased at an average cost of $52.52 per share, with a total value of $393,900.00. Following the completion of the transaction, the chief executive officer now directly owns 430,569 shares in the company, valued at approximately $22,613,483.88. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 9.20% of the company’s stock.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded up $1.15 during mid-day trading on Monday, reaching $47.41. 485,000 shares of the company’s stock were exchanged, compared to its average volume of 432,008. Ultragenyx Pharmaceutical Inc. has a 1 year low of $44.45 and a 1 year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, hitting the Zacks’ consensus estimate of ($1.87). The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period last year, the firm earned ($1.64) earnings per share. The company’s revenue for the quarter was up 81.8% compared to the same quarter last year. equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.24 EPS for the current year.

RARE has been the topic of a number of recent research reports. Canaccord Genuity reiterated a “buy” rating and issued a $83.00 price objective (down from $98.00) on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 22nd. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Stifel Nicolaus reiterated a “buy” rating and issued a $85.00 price objective (down from $95.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. J P Morgan Chase & Co set a $76.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a report on Wednesday, August 23rd. Finally, Robert W. Baird reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $71.31.

WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Shares Bought by Alps Advisors Inc.” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-inc-rare-shares-bought-by-alps-advisors-inc/1700074.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.